JE00BYSS4X48
© BusinessWire
22.12.2025
NVCR
LISTED
NASDAQ
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief Executive Officer, will present on behalf of the company and address questions on Wednesday, January 14, at 9:45 a.m. PST. Mr. Leonard will be joine...
Themefolio
Profiler
Peergroup
© BusinessWire
01.12.2025
NVCR
LISTED
NASDAQ
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
News Preview
Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company.
“During his more than 15-year career at Novocure, Frank has led many of our global business operatio...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2025
NVCR
LISTED
NASDAQ
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocure’s Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET, as well as one-on-one meetings with investors throughout the event.
A live audio...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
12.11.2025
NVCR
LISTED
NASDAQ
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer,...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
30.10.2025
NVCR
LISTED
NASDAQ
Novocure Reports Third Quarter 2025 Financial Results
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“Q3 was a solid quarter with stea...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
NVCR
LISTED
NASDAQ
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
News Preview
Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany.
At the EANO 202...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
NVCR
LISTED
NASDAQ
Novocure to Report Third Quarter 2025 Financial Results
News Preview
Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three- and nine-month periods that ended September 30, 2025.
T...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
NVCR
LISTED
NASDAQ
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
News Preview
Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) will be presented today at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting taking place September 27 – October 1 in San Francisco and simu...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
NVCR
LISTED
NASDAQ
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
News Preview
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.
“With the Mi...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2025
NVCR
LISTED
NASDAQ
Novocure Announces Upcoming Investor Events
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events.
2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event.
H.C. Wainwright...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
NVCR
LISTED
NASDAQ
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
News Preview
Novocure (NASDAQ: NVCR) announced today that Spain’s Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma.
“Glioblastoma is one of the most common and aggressive forms of primary brain cancer with few t...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
NVCR
LISTED
NASDAQ
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
News Preview
Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer.
This submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitan...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
24.07.2025
NVCR
LISTED
NASDAQ
Novocure Reports Second Quarter 2025 Financial Results
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“With the first half of 2025 complete...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
NVCR
LISTED
NASDAQ
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
News Preview
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer. These data from PANOVA-3 were accepted as a late-breaking abstract for oral presentation at the European Society for...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
NVCR
LISTED
NASDAQ
Novocure to Report Second Quarter 2025 Financial Results
News Preview
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company’s financial results for the three- and six-month periods that ended June 30, 2025.
To access th...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
NVCR
LISTED
NASDAQ
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
News Preview
Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology.
“The data presented today fro...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
NVCR
LISTED
NASDAQ
Novocure Announces Upcoming Investor Events
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreati...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
NVCR
LISTED
NASDAQ
Novocure Reports First Quarter 2025 Financial Results
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“This is a period of meaningful momentum fo...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
NVCR
LISTED
NASDAQ
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
News Preview
Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago.
The PANOVA-3 trial evaluated the use of TTFields th...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
NVCR
LISTED
NASDAQ
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
News Preview
Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen.
“Optune Lua is an innovative and urgent...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
NVCR
LISTED
NASDAQ
Novocure to Report First Quarter 2025 Financial Results
News Preview
Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company’s financial results for the three-month quarter that ended March 31, 2025.
To access the conferen...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
NVCR
LISTED
NASDAQ
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event.
A live audio webcast of this present...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
NVCR
LISTED
NASDAQ
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“Entering 2024, our team was fo...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
NVCR
LISTED
NASDAQ
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
News Preview
Novocure (NASDAQ: NVCR) announced today the official opening of its new global headquarters in the Canton of Zug, Switzerland. Novocure is an oncology company working to extend survival in some of the most aggressive forms of cancer, through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields).
The co...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
NVCR
LISTED
NASDAQ
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
News Preview
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFiel...
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
NVCR
LISTED
NASDAQ
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer, and William Doyle, Executive Chairman, will speak on behalf of the company and address questions at 9:00 a.m. PST. Ms. Cordova and Mr. Doyle will be j...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
NVCR
LISTED
NASDAQ
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
News Preview
Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line tr...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
NVCR
LISTED
NASDAQ
Novocure to Participate in Upcoming Investor Conferences
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences:
Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables, Florida. William Doyle, Executive Chairman, will take part in a fireside chat at 2:10 p.m. ET.
Piper Sandler Healthcare Conference on Thursday, Dec...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
NVCR
LISTED
NASDAQ
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
News Preview
Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas.
Novocure will present the results of its work to design arrays that will allow e...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
NVCR
LISTED
NASDAQ
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
News Preview
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM).
Optune Gio is a wearable, portable device that produces alternating electric fields known as Tum...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
NVCR
LISTED
NASDAQ
Novocure Appoints Christoph Brackmann as Chief Financial Officer
News Preview
Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO.
Mr. Brackmann joins Novocure fr...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
NVCR
LISTED
NASDAQ
Novocure Reports Third Quarter 2024 Financial Results
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“This was a period of strong execution...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
NVCR
LISTED
NASDAQ
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
News Preview
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
“Novocure is committed to ex...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
NVCR
LISTED
NASDAQ
Novocure to Report Third Quarter 2024 Financial Results
News Preview
Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three-month quarter and first nine months of the year t...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
NVCR
LISTED
NASDAQ
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
News Preview
Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain.
The results of the real-world analysis...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
NVCR
LISTED
NASDAQ
Novocure Announces Planned CEO Transition
News Preview
Novocure (NASDAQ: NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure’s Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company’s next CEO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
NVCR
LISTED
NASDAQ
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. William Doyle, Novocure’s Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors throughout the event.
A live audio webcast of this...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2024
NVCR
LISTED
NASDAQ
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
News Preview
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC) from September 7 – 10, 2024 in San Diego, California. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters explor...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
